Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717765 | 0.77 | JAK2 (0.46) | JAK2JAK3PDE10ACYP11B2KDM4E | |
| SCHEMBL14736721 | 0.77 | JAK2 (0.46) | JAK2JAK3PDE10ACYP11B2KDM4E | |
| SCHEMBL9941419 | 0.75 | JAK2 (0.45) | JAK2JAK3PDE10ACYP11B2 | |
| SCHEMBL14352211 | 0.74 | PDE10A (0.46) | JAK2JAK3PDE10ACYP11B2KDM4E | |
| SCHEMBL7147342 | 0.73 | PDE10A (0.46) | JAK2JAK3PDE10ACYP11B2KDM4E | |
| SCHEMBL10220083 | 0.73 | JAK2 (0.46) | JAK2JAK3PDE10ACYP11B2ADRA1B | |
| SCHEMBL14352106 | 0.72 | JAK2 (0.42) | JAK2JAK3PDE10ACYP11B2MEN1 | |
| SCHEMBL11413826 | 0.71 | PDE10A (0.44) | JAK2JAK3PDE10ACYP11B2MEN1 | |
| SCHEMBL11410227 | 0.71 | PDE10A (0.47) | JAK2JAK3PDE10ACYP11B2KDM4E | |
| SCHEMBL544142 | 0.70 | JAK2 (0.50) | JAK2JAK3PDE10ACYP11B2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-9540380-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150191476-A1 | Imidazotriazinone Compounds | FORUM PHARMACEUTICALS INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330014-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | JAK2 1925/4885JAK3 2249/4885PDE10A 14/4885 |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | JAK2 1925/4885JAK3 2249/4885PDE10A 14/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | JAK2 652/4885JAK3 924/4885PDE10A 13/4885 |
| US-20150191476-A1 | Imidazotriazinone Compounds | PDE9A, PDE12, PDE4A | JAK2 652/4885JAK3 924/4885PDE10A 13/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | JAK2 1925/4885JAK3 2249/4885PDE10A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.